Literature DB >> 25582453

Protocol for a multicentre, prospective, population-based cohort study of variation in practice of cholecystectomy and surgical outcomes (The CholeS study).

Ravinder S Vohra1, Philip Spreadborough2, Marianne Johnstone2, Paul Marriott2, Aneel Bhangu3, Derek Alderson4, Dion G Morton3, Ewen A Griffiths5.   

Abstract

INTRODUCTION: Cholecystectomy is one of the most common general surgical operations performed. Despite level one evidence supporting the role of cholecystectomy in the management of specific gallbladder diseases, practice varies between surgeons and hospitals. It is unknown whether these variations account for the differences in surgical outcomes seen in population-level retrospective data sets. This study aims to investigate surgical outcomes following acute, elective and delayed cholecystectomies in a multicentre, contemporary, prospective, population-based cohort. METHODS AND ANALYSIS: UK and Irish hospitals performing cholecystectomies will be recruited utilising trainee-led research collaboratives. Two months of consecutive, adult patient data will be included. The primary outcome measure of all-cause 30-day readmission rate will be used in this study. Thirty-day complication rates, bile leak rate, common bile duct injury, conversion to open surgery, duration of surgery and length of stay will be measured as secondary outcomes. Prospective data on over 8000 procedures is anticipated. Individual hospitals will be surveyed to determine local policies and service provision. Variations in outcomes will be investigated using regression modelling to adjust for confounders. ETHICS AND DISSEMINATION: Research ethics approval is not required for this study and has been confirmed by the online National Research Ethics Service (NRES) decision tool. This novel study will investigate how hospital-level surgical provision can affect patient outcomes, using a cross-sectional methodology. The results are essential to inform commissioning groups and implement changes within the National Health Service (NHS). Dissemination of the study protocol is primarily through the trainee-led research collaboratives and the Association of Upper Gastrointestinal Surgeons (AUGIS). Individual centres will have access to their own results and the collective results of the study will be published in peer-reviewed journals and presented at relevant surgical conferences. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Mesh:

Year:  2015        PMID: 25582453      PMCID: PMC4298090          DOI: 10.1136/bmjopen-2014-006399

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


A multicentre, prospective study, with independent validation of data. Capture of practice throughout the UK and Ireland. Data from all sizes of hospital and levels of specialist services. Inability to assess postoperative visits to general and family practitioners. Unable to capture the patients representing to other hospitals. Complications after 30 days not collected. Reason for acute surgery decision may not be fully elucidated.

Introduction

Cholecystectomy is one of the most commonly performed general surgical procedures in the UK. Approximately 66 000 cholecystectomies were performed during the 2011–2012 financial year in England alone.1 The pathway for these patients can be divided into three distinct groups: (1) acute admission with biliary disease and the cholecystectomy performed during that acute admission (acute group); (2) planned elective admission for cholecystectomy referred by their family doctor and added to the routine surgical waiting list from the outpatient department only (elective group) and (3) all other planned cholecystectomies performed on an elective operating list, who have had a previous emergency surgical admission with gallbladder (GB)-related disease (delayed group). This is shown in figure 1.
Figure 1

The pathway for patients who undergo cholecystectomy. Three groups of patients will be assessed: (1) acute admission with biliary disease and the cholecystectomy performed during that acute admission (acute group); (2) planned elective admission for cholecystectomy referred by their family doctor and added to the routine surgical waiting list from the outpatient department only (elective group) and (3) all other planned cholecystectomies performed on an elective operating list, who have had a previous emergency surgical admission with gallbladder-related disease (delayed group).

The pathway for patients who undergo cholecystectomy. Three groups of patients will be assessed: (1) acute admission with biliary disease and the cholecystectomy performed during that acute admission (acute group); (2) planned elective admission for cholecystectomy referred by their family doctor and added to the routine surgical waiting list from the outpatient department only (elective group) and (3) all other planned cholecystectomies performed on an elective operating list, who have had a previous emergency surgical admission with gallbladder-related disease (delayed group). The management of GB disease and whether patients have acute, elective or delayed operations varies widely between surgeons and hospitals.2–4 Level one evidence supports the role and safety of early or acute laparoscopic cholecystectomy in biliary colic, cholecystitis and gallstone pancreatitis.5–10 Population-level data from Hospital Episodes Statistics (HES) and a retrospective study from Scotland, both suggest however, that early or acute operations may be associated with poor surgical outcomes.2 3 These studies also suggest that differences in outcomes may be linked to hospital size and volume.2 3 Different surgical outcomes are commonly used to measure quality of healthcare, such as readmissions, reoperations and mortality. In particular, reducing hospital readmissions following surgery can lower hospital costs and improve patient satisfaction.11 The causes of readmission after cholecystectomy have been poorly studied, but are likely to vary by hospital size, case volume and whether patients have acute, elective or delayed operations performed.12 Taken together, this raises the possibility that trial evidence of common surgical procedures is not generalisable to population level, non-trial cohorts. Furthermore, differences in patient outcomes may be linked to hospital service provision. These factors both have an important impact on patients and the National Health Service (NHS), especially as trial data is in part used to inform commissioning decisions. It is not clear currently, why such variations occur in the NHS, or what the impact of these variations is on surgical outcomes.

Methods and analysis

Primary aim

To measure the difference in all-cause 30-day readmissions following acute, delayed and elective cholecystectomies in a contemporary, population-based cohort.

Hypothesis

The 30-day readmission rate, following risk adjustment, should be equivalent in patients following elective cholecystectomies compared with acute and delayed procedures.

Study design

We plan to undertake a multicentre, contemporary, prospective, cohort audit which will be conducted through trainee-led research collaboratives as described previously.13

Setting

This study can take place in any UK or Irish hospital performing acute, elective or delayed cholecystectomies. Each centre will contribute 2 months of consecutive patient data.

Participants

Inclusion criteria: All patients over the age of 18 years who are undergoing a cholecystectomy can be entered into this audit. Exclusion criteria: Patients having a cholecystectomy for known GB cancer, or as a part of another surgical procedure for example, Whipple's procedure, bariatric, antireflux or transplant operations, will be excluded.

Outcome measures

The primary outcome measure is all-cause 30-day readmission rate, which is defined as any admission following discharge which requires an overnight stay. This standard and definition is based on the Royal College of Surgeons (RCS) and the Association of Upper Gastrointestinal Surgeons (AUGIS) of Great Britain and Ireland guidance which states that the audit standard of less than 10% 30-day readmission rate should be reached by hospitals performing cholecystectomies.4 Secondary outcome measures are listed in table 1.
Table 1

Secondary outcome measures

Outcome measureDefinition
30 day all-cause postoperative complicationsAs described by the Clavien-Dindo classification of postoperative complications.15 Specifically bile leak, CBD injury, wound infection, intra-abdominal collection, pancreatitis, CBD stones, ICU/HDU readmissions will be collected, as will non-surgical complications such as cardiac, respiratory, urinary and other 30 day complications
Bile leakGraded: A—bile leak which requires little or no change in the patients management, resolves with conservative management within 7 days; B—bile leak or collection which requires additional diagnostic or interventional procedures, such as ERCP or relaparoscopy or Grade A which lasts >7 days; C—bile leak or collection which requires relaparotomy16
Bile duct injuryAny injury to the main biliary tree and will be classified using the Stewart-Way Classification System17:

1. Defined as incomplete injury to the CBD with no loss of duct

2. Defined as lateral damage to the CHD with either stricture formation or fistula (bile leak)

3. Defined as transection of the CBD with excision of a variable portion of the CBD and cystic duct/common duct junction

4. Defined as injury to the right hepatic duct with or without injury to the right hepatic artery

Conversion of operationLaparoscopic approach converted to anopen incision operation, or in which an abdominal incision to assist the procedure was needed
Duration of surgeryTime in minutes from skin incision to the end of skin closure
Length of stayCalculated from date of admission to date of discharge

CBD, common bile duct; CHD, common hepatic duct; ERCP, endoscopic retrograde cholangiopancreatography; HDU, high dependency unit; ICU, intensive care unit.

Secondary outcome measures 1. Defined as incomplete injury to the CBD with no loss of duct 2. Defined as lateral damage to the CHD with either stricture formation or fistula (bile leak) 3. Defined as transection of the CBD with excision of a variable portion of the CBD and cystic duct/common duct junction 4. Defined as injury to the right hepatic duct with or without injury to the right hepatic artery CBD, common bile duct; CHD, common hepatic duct; ERCP, endoscopic retrograde cholangiopancreatography; HDU, high dependency unit; ICU, intensive care unit.

Data collection

Data will be collected in a standardised Microsoft Excel spreadsheet. It will be the responsibility of the local investigators to ensure that the data is password protected and held on local trust computer systems. Each trust/hospital site will need to identify locations where laparoscopic cholecystectomy are performed (main theatre, day-case unit, treatment centre) to ensure full capture of cases during the audit period. Patients will be identified on a daily basis from the elective operating lists and by on-call teams, at handovers, from on-call lists and from emergency theatre booking lists and logbooks. Operative data should be completed either by or with input from the operating surgeon or the assistant. All patients will be followed for 30 days following their operation. The hospital's electronic or paper records should be checked by the team to identify any readmissions or reattendances to the hospital's emergency department, surgical assessment unit or wards. Local arrangements may include: Reviewing the patient or patient's notes during admission to identify inpatient complications. Check the discharge summary or letter to check for any postoperative complications. Check for any outpatient attendances within 30 days of surgery. Check electronic or paper hospital records or handover lists for reattendances or readmissions. Check for any accident and emergency department reattendances. Review imaging reports or laboratory results to check for unplanned attendances which may have occurred.

Data validation and management

Following data collection, only data sets with >95% data completeness will be accepted for pooled national analysis. The consultant surgeon principle investigator (PI) at selected sites will identify an independent assessor to validate all data points, with a target of >98% accuracy. Overall, at least 5% of the data set will be independently validated. In addition, the independent assessor will be asked to examine operating theatre logbooks and trust data systems, to ensure case ascertainment. If the concordance between the total number of cases submitted to the trial management group is <95%, the hospital's data will be removed from the analysis. A standardised Microsoft Excel spreadsheet (Excel 2007; Microsoft, Redmond, Washington, USA) with preset fields will be used to collect the data. Data protection regulations at each centre will be complied with. Patient identifiable data will not be transmitted to the trial management group. Data will be submitted centrally via a secure NHS email address with all patient identifiers removed. Patient anonymised data will be then be analysed and reported by the writing committee. Outcome data specific to each individual surgeon who participates will not be collected. Anonymised hospital data will be compared; individual surgeons, hospitals or NHS Trusts will not be identified. The required anonymous data fields are shown in table 2. Individual centres will be surveyed at the end of the audit period to determine local policies and service provision (table 3). Anonymous patient-level data will be linked to the results of the hospital service survey to allow detailed analysis of these variables and patient outcome.
Table 2

Data fields

FieldOptions (definitions)
AgeIn years
GenderMale, female
Body mass indexIndividual's body mass will be subclassified as:

Underweight (<17.9 kg/m2)

Normal (18.0–24.9 kg/m2)

Overweight (25.0–29.9 kg/m2)

Moderate obesity (30.0–34.9 kg/m2)

Severe obesity (35.0–39.9 kg/m2)

Very severe obesity (>40.0 kg/m2)

ASA scoreClassified as:

1. A normal healthy patient

2. A patient with mild systemic disease

3. A patient with severe systemic disease

4. A patient with severe systemic disease that is a constant threat to life

5. A moribund patient who is not expected to survive without the operation

Admission dateDay/month/year
Operation dateDay/month/year
Timing of surgeryClassified as: acute; elective or delayed elective
Planned day-caseYes (defined as patients who are planned to be admitted and discharged on the same day as the operation)
Date decision made to operateFor ‘elective’ cases this will be the date the patient was seen in the outpatient clinic. For ‘delayed’ cases this is the date the patient was last discharged from hospital with biliary disease. For ‘acute’ cases this should be the date the decision was made to perform an acute cholecystectomy in that emergency admission
Preoperative indicationBiliary colic (the presence of colicky right upper quadrant pain associated with gallstones or sludge on an USS, but no signs of acute cholecystitis)Acute or chronic cholecystitis current or previous clinical or ultrasound evidence of cholecystitis (thick-walled GB and/or pericholecystitis, USS tenderness over the GB, the presence of gallstones)Gallstone pancreatitis (pancreatitis secondary to gallstones. Should be diagnosed using the Atlanta guidelines which state the diagnosis of acute pancreatitis requires two of the following three features: (1) abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epigastric pain often radiating to the back); (2) serum lipase activity (or amylase activity) at least three times greater than the upper limit of normal; and (3) characteristic findings of acute pancreatitis on contrast-enhanced CT)18CBD stones (as confirmed by preoperative imaging, that may or may not have been removed preoperatively)GB polyps (hyperechoic lesions on USS imaging which have no acoustic shadowing and do not move with positional changes (and have no features of overt malignancy))Dyskinesia (biliary-like abdominal pain, occurring in a normal appearing GB with a functional HIDA scan showing an abnormal GB ejection fraction of less than 40%)Acalculous cholecystitis (clinical or ultrasound evidence (thick-walled GB and/or pericholecystitis, USS tenderness over the GB, the absence of gallstones))
Surgical admissions with biliary symptoms in the previous 12 monthsNumber of surgical admissions with biliary symptoms in the previous 12 months: 0, 1, 2, 3, 4, 5, >6Total number of days spent in hospital as a resultDate of last discharge (if applicable)
Investigations

USS

CT

MR cholangiopancreatography

Endoscopic retrograde cholangiopancreatography

Endoscopic USS

Functional scan

Seniority of surgeons

<Specialty trainee (ST6)

ST6 or above or staff grade

Consultant

Perioperative antibioticsYes/no
Method of operation

Laparoscopic

Laparoscopic converted to open

Open cholecystectomy

SILS

Degree of difficultyNassar scale of difficulty for cholecystectomy graded 1, 2, 3, 419Grade I Floppy, non-adherent gallbladder. Clear, thin cystic pedicle. Simple adhesions to neck and Hartmann's pouch onlyGrade II Mucocele; packed with stones gallbladder. Fat-laden cystic pedicle. Simple adhesions, up to the body of gallbladderGrade III Deep fossa; acute cholecystitis; contracted, fibrousHartmann's pouch adherent to CBD or with stone impaction.Abnormal anatomy; cystic duct short, dilated or obscured.Dense adhesions, up to the fundus; involving hepatic flexure or duodenumGrade IV Completely obscured gallbladder; empyema/gangreneOr mass. Impossible to clarify cystic pedicle. Dense, fibrous adhesions wrapping the GB. Duodenum or hepatic flexure difficult to separate
Intraoperative complications

Bile spilt (intra-abdominal spillage of bile during the procedure, including when removing the GB from the abdominal cavity)

Stones spilt (intra-abdominal spillage of stones during the procedure, including as removing the GB from the abdominal cavity)

Bleeding (requiring haemostatic agents (eg, Surgicel, Fibrillar, etc), extra clips, suturing or conversion to open procedure)

CBD injury (will be defined as any injury to the main biliary tree and will be classified using the Stewart-Way Classification System (1, 2, 3, 4))

Intraoperative cholangiography

Planned (defined as the decision to perform a cholangiogram before the operation starts; eg, due to surgeon preference or to assess for CBD stones)

Unplanned (defined as any other reason where a cholangiogram was performed but was not anticipated at the start of the operation; eg, to assess for unclear anatomy or to assess for potential CBD injury)

CBD explorationYes/no
Abdominal drainYes/no
Date of dischargeDay/month/year
All-cause 30-day A&E attendanceYes/no
All 30-day reinterventions and reimagingYes/no
30-day mortalityYes/no

A&E, accident and emergency department; ASA, American Society of Anesthesiologist; CBD, common bile duct; GB, gallbladder; HIDA, hepatobiliary iminodiacetic acid; SILS, single-incision laparoscopic surgery; USS, ultrasound scan.

Table 3

Hospital-level variables

FieldOption (definition)
LocationEngland; Scotland; Wales; Northern Ireland; Republic of Ireland
University hospitalYes/no
Total number of beds<100; 100–500; 500–1000; >1000
Tertiary HPB servicesYes/no
ERCP servicesYes/no
Acute admissionsYes/no
Number of consultants on the general surgery on-call rotaNumber
Consultant specialties involved in performing cholecystectomiesOesophagogastric
Hepatobiliary
Colorectal
Breast
Vascular
Endocrine
General
Transplant
Other
Number of consultant surgeons offering cholecystectomyNumber
Number of consultant surgeons offering acute/emergency cholecystectomyNumber
Number of consultant surgeons offering laparoscopic CBD explorationNumber
Does your hospital offer dedicated ‘hot’ gallbladder theatre listsYes/no
Performing an intraoperative cholangiographyYes/no
Additional hospital services availableMRCP
Endoscopic USS
Functional scans
Radiological drainage
Percutaneous transhepatic cholangiograms
Radiological cholecystostomy

CBD, common bile duct; ERCP, endoscopic retrograde cholangiopancreatography; HPB, hepato-pancreato-biliary; MRCP, MR cholangiopancreatography; USS, ultrasound scan.

Data fields Underweight (<17.9 kg/m2) Normal (18.0–24.9 kg/m2) Overweight (25.0–29.9 kg/m2) Moderate obesity (30.0–34.9 kg/m2) Severe obesity (35.0–39.9 kg/m2) Very severe obesity (>40.0 kg/m2) 1. A normal healthy patient 2. A patient with mild systemic disease 3. A patient with severe systemic disease 4. A patient with severe systemic disease that is a constant threat to life 5. A moribund patient who is not expected to survive without the operation USS CT MR cholangiopancreatography Endoscopic retrograde cholangiopancreatography Endoscopic USS Functional scan ST6 or above or staff grade Consultant Laparoscopic Laparoscopic converted to open Open cholecystectomy SILS Bile spilt (intra-abdominal spillage of bile during the procedure, including when removing the GB from the abdominal cavity) Stones spilt (intra-abdominal spillage of stones during the procedure, including as removing the GB from the abdominal cavity) Bleeding (requiring haemostatic agents (eg, Surgicel, Fibrillar, etc), extra clips, suturing or conversion to open procedure) CBD injury (will be defined as any injury to the main biliary tree and will be classified using the Stewart-Way Classification System (1, 2, 3, 4)) Planned (defined as the decision to perform a cholangiogram before the operation starts; eg, due to surgeon preference or to assess for CBD stones) Unplanned (defined as any other reason where a cholangiogram was performed but was not anticipated at the start of the operation; eg, to assess for unclear anatomy or to assess for potential CBD injury) A&E, accident and emergency department; ASA, American Society of Anesthesiologist; CBD, common bile duct; GB, gallbladder; HIDA, hepatobiliary iminodiacetic acid; SILS, single-incision laparoscopic surgery; USS, ultrasound scan. Hospital-level variables CBD, common bile duct; ERCP, endoscopic retrograde cholangiopancreatography; HPB, hepato-pancreato-biliary; MRCP, MR cholangiopancreatography; USS, ultrasound scan.

Anticipated recruitment

On the basis of cholecystectomy-specific HES data from England, 66 000 procedures were coded during the 2011–2012 financial year.1 If there is a uniform distribution of procedures performed between each of the acute care trusts and all hospitals in the UK and Ireland participate, data on 11 000 procedures could be potentially gathered prospectively. Minimum expected recruitment would be approximately 1500 procedures from 20 centres from the West Midlands.

Study timeline

Data collection and analysis will be performed using the following timelines: 4 November 2013–11 December 2013—Pilot study period. 1 March 2014–1 May 2014—Main study data collection period. 1 June 2014—Main study 30-day follow-up period ends. 31 August 2014—Central data submission anticipated being complete. 20 December 2014—Independent data validation anticipated being complete. 28 February 2015—Initial data analysis anticipated being complete.

Statistical analysis

The report of this study will be prepared in accordance to guidelines set by the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement for observational studies.14 Data will be collected and analysed in clinically relevant categories, and χ2 tests used to detect differences between groups. Missing data will be analysed and multiple imputation used if required. Binary logistic regression modelling will be used to adjust the influence of timing of surgery for key confounding variables. Data will be adjusted for patient (age, gender, American Society of Anesthesiologist (ASA) score and body mass index), disease (indication, ultrasound scan findings, the need of other imaging and endoscopic retrograde cholangiopancreatography (ERCP)), surgeon (consultant present, specialty and number of surgeons performing cholecystectomy) and hospital (number of hospital beds, university hospital, tertiary hepato-pancreato-biliary services, acute admissions, ERCP services and ‘Hot’ GB lists) factors. Multivariate models will be built to produce ORs to account for the impact of predictive variables when assessing outcomes. The OR represents the odds of all-cause 30-day readmission occurring, comparing the experimental groups (acute and delayed) versus the reference group (elective). A second model will compare acute cholecystectomy against a reference of delayed cholecystectomy. Variable selection including hospital-level data will be based on those which are statistically significant at univariate analysis, and those which are clinically significant, but not statistically. Depending on data requirements, models will be developed using fixed-entry binary logistic regression, multilevel modelling and multiply imputed data sets, to compare outputs based on statistical technique. The main strength of this project is the multicentre, prospective, contemporary methodology with independent validation of the data. This will give high quality, validated data on cholecystectomy provision and outcome throughout the UK and Ireland from a wide range of hospital types. Limitations include the inability to assess postoperative visits to the general practitioner. In addition, a minority of patients will re-present to other hospitals with complications following surgery. However, during the audit period, teams will also document the absolute number of patients readmitted with complications from cholecystectomy performed at other hospitals. Our study uses the standard 30 day follow-up period as this is the international standard and allows comparison with other studies. However, complications which may occur after 30 days, such as retained common bile duct stones or late biliary strictures will not be reported. In the acute group, it may not be possible to fully elucidate whether the decision to operate was due to hospital policies, surgeon preference or patient-related factors. However, we will collect data on patient, disease, surgeon and hospital factors to assess which is associated with acute cholecystectomy.

Discussion

Variations in outcomes following common surgical procedures such as cholecystectomy are a concern for the NHS. This paper describes the protocol for a novel study to investigate how hospital-level surgical provision can affect patient outcomes using cross-sectional methodology. The results of this audit are essential to inform commissioning groups and implement changes within the NHS. Furthermore, the development of consultant PIs across the UK enables a network of new investigators who can be approached to collaborate on further studies.

Ethics and dissemination

The proposed study will not affect clinical care and compares an outcome to a defined audit standard. Research ethics approval is not required for this study and this has been confirmed by the use of the online National Research Ethics Service (NRES) decision tool (http://www.hra-decisiontools.org.uk/research/). This has been further supported by written confirmation and advice from the Research and Development Director at University Hospitals Birmingham NHS Foundation Trust, UK. The study will be registered as a clinical audit or service evaluation at each participating hospital. Patient consent is not deemed necessary and inclusion in the study will not incur any risk to individual patients. The generic collaborative methodology underlying protocol dissemination and collaborator recruitment has been described previously.13 The protocol will be disseminated primarily through the trainee-led research collaboratives (http://www.asit.org/resources/collaboratives), and members of the Association of Surgeons in Training (ASIT; http://www.asit.org), AUGIS (http://www.augist.org) and the Schoolofsurgery.org (http://www.schoolofsurgery.org). A consultant surgeon PI will be designated at each hospital to facilitate coordination of the study. The protocol document and data collection tools will be made available online (http://www.choles-study.org). Individual centres will have access to their own results and the collective results of the study will be published in peer-reviewed journals and presented at relevant surgical conferences. These results can then be used to inform commissioning and implement changes within the NHS.
  16 in total

Review 1.  Causes and prevention of laparoscopic bile duct injuries: analysis of 252 cases from a human factors and cognitive psychology perspective.

Authors:  Lawrence W Way; Lygia Stewart; Walter Gantert; Kingsway Liu; Crystine M Lee; Karen Whang; John G Hunter
Journal:  Ann Surg       Date:  2003-04       Impact factor: 12.969

2.  Early versus delayed laparoscopic cholecystectomy for acute cholecystitis: a meta-analysis of randomized clinical trials.

Authors:  Tamim Siddiqui; Alisdair MacDonald; Peter S Chong; John T Jenkins
Journal:  Am J Surg       Date:  2008-01       Impact factor: 2.565

Review 3.  Meta-analysis of randomized controlled trials on the safety and effectiveness of early versus delayed laparoscopic cholecystectomy for acute cholecystitis.

Authors:  K Gurusamy; K Samraj; C Gluud; E Wilson; B R Davidson
Journal:  Br J Surg       Date:  2010-02       Impact factor: 6.939

4.  Prospective randomized trial using cost-utility analysis of early versus delayed laparoscopic cholecystectomy for acute gallbladder disease.

Authors:  D A L Macafee; D J Humes; G Bouliotis; I J Beckingham; D K Whynes; D N Lobo
Journal:  Br J Surg       Date:  2009-09       Impact factor: 6.939

5.  Epidemiological study of provision of cholecystectomy in England from 2000 to 2009: retrospective analysis of Hospital Episode Statistics.

Authors:  Sidhartha Sinha; David Hofman; David L Stoker; Peter J Friend; Jan D Poloniecki; Matt M Thompson; Peter J E Holt
Journal:  Surg Endosc       Date:  2012-07-18       Impact factor: 4.584

6.  Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery.

Authors:  Moritz Koch; O James Garden; Robert Padbury; Nuh N Rahbari; Rene Adam; Lorenzo Capussotti; Sheung Tat Fan; Yukihiro Yokoyama; Michael Crawford; Masatoshi Makuuchi; Christopher Christophi; Simon Banting; Mark Brooke-Smith; Val Usatoff; Masato Nagino; Guy Maddern; Thomas J Hugh; Jean-Nicolas Vauthey; Paul Greig; Myrddin Rees; Yuji Nimura; Joan Figueras; Ronald P DeMatteo; Markus W Büchler; Jürgen Weitz
Journal:  Surgery       Date:  2011-02-12       Impact factor: 3.982

7.  The relationship between timing of surgical complications and hospital readmission.

Authors:  Melanie S Morris; Rhiannon J Deierhoi; Joshua S Richman; Laura K Altom; Mary T Hawn
Journal:  JAMA Surg       Date:  2014-04       Impact factor: 14.766

8.  Variation in surgical-readmission rates and quality of hospital care.

Authors:  Thomas C Tsai; Karen E Joynt; E John Orav; Atul A Gawande; Ashish K Jha
Journal:  N Engl J Med       Date:  2013-09-19       Impact factor: 91.245

9.  Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus.

Authors:  Peter A Banks; Thomas L Bollen; Christos Dervenis; Hein G Gooszen; Colin D Johnson; Michael G Sarr; Gregory G Tsiotos; Santhi Swaroop Vege
Journal:  Gut       Date:  2012-10-25       Impact factor: 23.059

10.  Hospital volume and patient outcomes after cholecystectomy in Scotland: retrospective, national population based study.

Authors:  Ewen M Harrison; Stephen O'Neill; Thomas S Meurs; Pang L Wong; Mark Duxbury; Simon Paterson-Brown; Stephen J Wigmore; O James Garden
Journal:  BMJ       Date:  2012-05-23
View more
  12 in total

1.  Current practice of antibiotic prophylaxis during elective laparoscopic cholecystectomy.

Authors:  Caw Macano; E A Griffiths; R S Vohra
Journal:  Ann R Coll Surg Engl       Date:  2017-01-10       Impact factor: 1.891

2.  Preoperative risk factors for conversion from laparoscopic to open cholecystectomy: a validated risk score derived from a prospective U.K. database of 8820 patients.

Authors:  Robert P Sutcliffe; Marianne Hollyman; James Hodson; Glenn Bonney; Ravi S Vohra; Ewen A Griffiths
Journal:  HPB (Oxford)       Date:  2016-08-31       Impact factor: 3.647

Review 3.  A mapping review of sacrococcygeal pilonidal sinus disease.

Authors:  M Kumar; W H Clay; M J Lee; S R Brown; D Hind
Journal:  Tech Coloproctol       Date:  2021-03-16       Impact factor: 3.781

4.  Comparison of short-term outcomes from the International Oesophago-Gastric Anastomosis Audit (OGAA), the Esophagectomy Complications Consensus Group (ECCG), and the Dutch Upper Gastrointestinal Cancer Audit (DUCA).

Authors: 
Journal:  BJS Open       Date:  2021-05-07

5.  The iBRA-2 (immediate breast reconstruction and adjuvant therapy audit) study: protocol for a prospective national multicentre cohort study to evaluate the impact of immediate breast reconstruction on the delivery of adjuvant therapy.

Authors:  Rajiv Dave; Rachel O'Connell; Tim Rattay; Zoe Tolkien; Nicola Barnes; Joanna Skillman; Paula Williamson; Elizabeth Conroy; Matthew Gardiner; Adrian Harnett; Ciara O'Brien; Jane Blazeby; Shelley Potter; Chris Holcombe
Journal:  BMJ Open       Date:  2016-10-07       Impact factor: 2.692

6.  Effectiveness of Antibiotic Prophylaxis in Non-emergency Cholecystectomy Using Data from a Population-Based Cohort Study.

Authors:  Ravinder S Vohra; James Hodson; Sandro Pasquali; Ewen A Griffiths
Journal:  World J Surg       Date:  2017-09       Impact factor: 3.352

7.  Utilisation of an operative difficulty grading scale for laparoscopic cholecystectomy.

Authors:  Ewen A Griffiths; James Hodson; Ravi S Vohra; Paul Marriott; Tarek Katbeh; Samer Zino; Ahmad H M Nassar
Journal:  Surg Endosc       Date:  2018-06-28       Impact factor: 4.584

8.  Postoperative pulmonary complications following major elective abdominal surgery: a cohort study.

Authors:  Kamlesh Patel; Fatemeh Hadian; Aysha Ali; Graham Broadley; Kate Evans; Claire Horder; Marianne Johnstone; Fiona Langlands; Jake Matthews; Prithish Narayan; Priya Rallon; Charlotte Roberts; Sonali Shah; Ravinder Vohra
Journal:  Perioper Med (Lond)       Date:  2016-05-23

9.  The development and validation of a scoring tool to predict the operative duration of elective laparoscopic cholecystectomy.

Authors:  Reshma Bharamgoudar; Aniket Sonsale; James Hodson; Ewen Griffiths
Journal:  Surg Endosc       Date:  2018-01-16       Impact factor: 4.584

10.  The NeST (neoadjuvant systemic therapy in breast cancer) study - Protocol for a prospective multi-centre cohort study to assess the current utilization and short-term outcomes of neoadjuvant systemic therapies in breast cancer.

Authors:  G W Irwin; F Bannon; C E Coles; E Copson; R I Cutress; R V Dave; M Grayson; C Holcombe; S Irshad; C O'Brien; R L O'Connell; C Palmieri; A M Shaaban; N Sharma; J Singh; I Whitehead; S Potter; S A McIntosh
Journal:  Int J Surg Protoc       Date:  2019-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.